Abstract:Background: Thalassemia syndromes are inherited hemoglobin disorders that result when the synthesis of normal hemoglobin is lacking or significantly reduced. For people with thalassemia, long-term red blood cell transfusion remains the mainstay of therapy, which may lead to iron overload causing severe complications and damage in different body organs. Long-term iron chelation therapy is essential for people with thalassemia to minimize the ongoing iron-loading process. In addition, suboptimal adherence can increase adverse events associated with iron overload and result in increased morbidity, mortality, healthcare utilization and cost of care. Objectives: To identify and assess the effects of computer and mobile technology interventions designed to facilitate medication adherence and disease management in individuals with thalassemia, including:- evaluating the effects of using computer and mobile technology interventions for medication adherence and disease management on health and behavioral outcomes;- identifying and assessing the effects of computer and mobile technology interventions specific to different age groups (children, adolescents and adults) and type of modality (e.g. cell phone, the Internet). Search methods: We searched CENTRAL (the Cochrane Library), MEDLINE, Embase, CINAHL, PsycINFO, ProQuest Dissertations & Theses Global, Psychology and Behavioral Sciences Collection, Web of Science Science & Social Sciences Conference Proceedings Indexes, IEEE Xplore and ongoing trial databases (22 February 2018). We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register (20 June 2019). We also searched for unpublished work in the abstract book of nine major conferences in the related field. Selection criteria: Randomized controlled trials (RCT) and quasi-RCTs comparing single- or multi-component interventions versus no intervention, placebo or standard care, with adherence to iron chelation as the primary outcome were eligible for inclusion. Non-randomized studies of interventions, controlled before-after studies, and interrupted-time-series studies were also eligible for inclusion. Data collection and analysis: Three authors independently assessed study eligibility. If we had included any studies, we would have independently assessed risk of bias and extracted data; we planned to assess the quality of the evidence using GRADE. Main results: We did not identify any eligible studies for inclusion in the review. Authors' conclusions: Due to lack of evidence, we cannot comment on the efficacy or effectiveness of computer and mobile technology intervention strategies to promote disease management and adherence to iron chelation therapy in people with thalassemia.We concluded that RCTs are needed to examine a variety of computer and mobile technology intervention strategies that may be useful for promoting disease management and increasing adherence to iron chelation therapy in individuals with thalassemia.

The impact of chelation compliance in health outcome and health related quality of life in thalassaemia patients: a systematic review

A systematic review of adherence to iron chelation therapy among children and adolescents with thalassemia

Adherence to Iron Chelation Therapy among Adults with Thalassemia: A Systematic Review

Adherence to Iron Chelation Therapy and Its Determinants

Clinical and health-related quality of life outcomes of transfusion-dependent thalassaemia patients in Singapore

The effect of iron chelation therapy on overall survival in sickle cell disease and β-thalassemia: A systematic review

Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia

The challenges of adherence and persistence with iron chelation therapy

Promoting Adherence to Iron Chelation Treatment in Beta-Thalassemia Patients

Clinical Challenges with Iron Chelation in Beta Thalassemia

Awareness and practical evaluation of correct use of iron chelators; a study to track the ambiguities of thalassemia patients on their medications in Iran

Computer and mobile technology interventions to promote medication adherence and disease management in people with thalassemia

Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia

Iron overload: the Achilles heel of β- thalassemia

Patient Perspective on Iron Chelation Therapy: Barriers and Facilitators of Medication Adherence

Iron Chelator in Patients with Sickle Cell Anemia, Comparative Study

Differential effects of iron chelators on iron burden and long-term morbidity and mortality outcomes in a large cohort of transfusion-dependent β-thalassemia patients who remained on the same monotherapy over 10 years

Combined chelation therapy in thalassemia major with deferiprone and desferrioxamine: a retrospective study

Health‐related quality of life with standard and curative therapies in thalassemia: A narrative literature review

From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox

Decision points in the treatment of transfusional iron overload in patients with myelodysplastic syndromes: why, when, and how to chelate